SCHEMBL8290481

SCHEMBL8290481

O=C(N/N=C/c1ccco1)c1ccc(F)cc1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.76
KMT2A Q03164 3/20 0.76
GAA P10253 2/20 0.76
MEN1 O00255 2/20 0.76
PKM P14618 2/20 0.76
CYP1A2 P05177 1/20 0.72
TDP1 Q9NUW8 4/20 0.67
POLB P06746 3/20 0.65
CTDSP1 Q9GZU7 2/20 0.65
AHR P35869 1/20 0.65
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
ALDH1A1 P00352 1/20 0.60
MGAM O43451 1/20 0.59
HTT P42858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8290446 0.88 CYP1A2 (0.72) MAPTKMT2AGAAMEN1PKM
SCHEMBL1562660 0.88 CYP1A2 (0.76) MAPTKMT2AGAAMEN1PKM
SCHEMBL1562661 0.88 CYP1A2 (0.76) MAPTKMT2AGAAMEN1PKM
SCHEMBL6635372 0.88 CYP1A2 (0.76) MAPTKMT2AGAAMEN1PKM
SCHEMBL8291227 0.87 TDP1 (0.85) MAPTKMT2AGAAMEN1PKM
SCHEMBL8292186 0.87 CYP1A2 (0.71) MAPTKMT2AGAAMEN1PKM
SCHEMBL8292509 0.87 GAA (0.71) MAPTKMT2AGAAMEN1PKM
SCHEMBL21258283 0.87 CYP1A2 (0.71) MAPTKMT2AGAAMEN1PKM
SCHEMBL8291209 0.87 MEN1 (0.77) MAPTKMT2AGAAMEN1PKM
SCHEMBL13497052 0.86 HTT (0.67) MAPTKMT2AGAAMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281129-A1 CDKI PATHWAY INHIBITORS AND USES THEREOF SENEX BIOTECHNOLOGY, INC. 2009-11-12 US disclosed
US-20080033000-A1 Identification of CDKI pathway inhibitors SENEX BIOTECHNOLOGY, INC. 2008-02-07 US disclosed
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
WO-2005037257-A2 NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES IMTM GMBH (DE) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281129-A1 CDKI PATHWAY INHIBITORS AND USES THEREOF CDKN1A, CDK6, CCNI MAPT 1424/4885KMT2A 883/4885GAA 1316/4885
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases DNPEP, PREP, ANPEP MAPT 1400/4885KMT2A 3390/4885GAA 227/4885
US-20080033000-A1 Identification of CDKI pathway inhibitors CDKN1A, CDK6, CDK2 MAPT 1548/4885KMT2A 1164/4885GAA 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.